Clinical trials: Sertraline
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).
- Trial name
- NCT01254305
- Testing
- Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine.
- Where
- 20 sites in United States
- Volunteers
- 262 people
- Sponsor
- Forest Laboratories
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Depression
Bioequivalency Study of Sertraline Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Sertraline Tablets, 100 mg, to Zoloft® Tablets, 100 mg (Pfizer) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00602849
- Testing
- Sertraline
- Where
- Canada
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Chronic Kidney Disease (CKD), Elderly
Sertraline and the Risk of Serious Adverse Events
The goal of this population-based cohort study is to assess the safety of initiating a new outpatient prescription of 50 mg/day of Sertraline, a higher dose, compared to 25 mg/day, a lower dose, in adults aged 65+ with low kidney…
- Conditions
- Chronic Kidney Disease (CKD), Elderly, Outpatient
- Trial name
- NCT07387120
- Testing
- Sertraline 50 mg, Sertraline 25 mg
- Where
- Canada
- Volunteers
- 6,893 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Depression, Anxiety Disorder
Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment
The aim of the study is to determine the influence of supplementation of probiotic Lactobacillus Plantarum 299V vs. placebo of probiotic during antidepressant monotherapy with SSRI (Selective Serotonin Reuptake Inhibitor) in…
- Trial name
- NCT02469545
- Testing
- Lactobacillus Plantarum 299v, Crystalline cellulose powder, Escitalopram
- Where
- Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Bialystok
Dementia
Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD)
Dementia refers to a condition where there is a loss of intellectual function (cognition). It is usually a progressive condition that interferes with normal social and occupational activities.
- Trial name
- NCT00001777
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Panic Disorder
Therapies for Treatment-Resistant Panic Disorder Symptoms
This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.
- Trial name
- NCT00118417
- Testing
- Clonazepam, Sertraline, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Emotional Distress
Mechanism of Mindfulness Based Online Intervention in Reducing Emotional Distress
This study hopes to: 1. explore whether, at the individual level, the improvement of mindfulness ability can promote peace of mind, reduce the frequency of mental wandering, weaken or cut off the cycle between negative mood and…
- Trial name
- NCT05600790
- Testing
- Mindfulness Intervention for Emotional Distress
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University
Autism
Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?
The purpose of this study is to determine if fluvoxamine or sertraline reduce the fequency or severity of aggressive behaviour, obsessive symptoms, or anxiety in young children with autism.
- Trial name
- NCT00655174
- Testing
- fluvoxamine, sertraline
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- The Hospital for Sick Children
Neurodevelopmental Disorders, Autism
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare.
- Conditions
- Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder, Fragile X Syndrome
- Trial name
- CALM (NCT06081348)
- Testing
- Sertraline
- Where
- 7 sites in Canada
- Volunteers
- 130 people
- Sponsor
- Holland Bloorview Kids Rehabilitation Hospital
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Patients With Mild to Moderate GAD
Effects of Saffron on Mild to Moderate Generalized Anxiety Disorder (GAD)
anxiety disorder is one of the major public health problems worldwide. 25% of people experience anxiety disorders throughout life. Generalized anxiety disorder (GAD) is known as the most prevalent anxiety disorder.
- Trial name
- NCT02800733
- Testing
- Saffron
- Volunteers
- 40 people
- Sponsor
- National Nutrition and Food Technology Institute
Depression Disorder
Estimation of Control Before and After Treatment of a Depressive Episode With Serotonin Reuptake Inhibitors
The goal of this observational study is to better understand cognitive and affective processes involved in depression, in particular how individuals estimate their perception of control over events in their environment, as well…
- Trial name
- APTE-Sero (NCT07716982)
- Testing
- Selective Serotonin Reuptake Inhibitors (SSRIs) or serotonergic antidepressants, Experimental tasks
- Where
- France
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Depression
Allopurinol in Depression
Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs.
- Trial name
- NCT07574060
- Testing
- Sertraline 50 MG, Allopurinol 300 MG
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
Panic Disorder
Special Investigation Of J Zoloft For Panic Disorder Patients
The objective of this surveillance is to collect information for panic disorder patients about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in…
- Trial name
- NCT00605917
- Testing
- Sertraline hydrochloride
- Volunteers
- 997 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder (MDD
Psychoeducational Group for Depression
The study aims to investigate the efficacy of a psychoeducational program as an adjunctive treatment for depression. The study will involve 338 patients diagnosed with Major Depressive Disorder (MDD) of moderate severity.
- Trial name
- PEG-D (NCT06467474)
- Testing
- PEG-D program, TAU
- Where
- Brazil
- Volunteers
- 338 people
- Sponsor
- Ricardo Alberto Moreno, M.D., Ph.D.
Depression - Major Depressive Disorder, Depressive Episodes
TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children
Depression in childhood and adolescence is a serious and increasing public-health problem associated with profound short- and long-term consequences, including impaired social and educational functioning, increased risk of…
- Trial name
- NCT07478796
- Testing
- Fluoxetine, Escitalopram, Sertralin
- Where
- Poland
- Volunteers
- 180 people
- Sponsor
- Poznan University of Medical Sciences
Healthy
Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fed Conditions
Objective: To compare the rate and extent of absorption of Torrent Pharmaceuticals Limited, India, sertraline and Pfizer, Inc., USA (Zoloft) sertaline, administered as a 1X100 mg tablet, under fasted conditions.
- Trial name
- NCT00946036
- Testing
- Sertraline Hydrochloride
- Where
- Canada
- Sponsor
- Torrent Pharmaceuticals Limited
Schizophrenia and Related Disorders, Major Depressive Disorder
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros.
- Conditions
- Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
- Trial name
- INTENSIFY (NCT05603104)
- Testing
- Clozapine, Esketamine Nasal Product, Escitalopram
- Where
- Israel
- Volunteers
- 1,254 people
- Sponsor
- Dr. Inge Winter
Chronic Low Back Pain, Negative Affectivity
Treating Negative Affect in Low Back Pain Patients
This study will examine how the use of antidepressant, physical therapy, and combination of both affects pain, function, and depression outcomes in chronic low back pain patients.
- Trial name
- TNA-LBP (NCT04747314)
- Testing
- Antidepressant, Enhanced Fear Avoidance Rehabilitation
- Where
- 3 sites in United States
- Volunteers
- 308 people
- Sponsor
- Ajay Wasan, MD, Msc